Bone Marrow MMP-9 Expression Mediates Therapeutic Effect of Selective CXCR4 Antagonist AMD3100 on Myocardial Infarction

被引：0
|
作者：
Jujo, Kentaro [1 ]
Ii, Masaaki [2 ]
Sekiguchi, Haruki [1 ]
Hamada, Hiromichi [1 ]
Thorne, Tina [1 ]
Klyachko, Ekaterina [1 ]
Clarke, Trevor [1 ]
Ito, Aiko [1 ]
Misener, Sol [1 ]
Renault, Marie-Ange [1 ]
Losordo, Douglas W. [1 ]
机构：
[1] Northwestern Univ, Feinberg Sch, Chicago, IL 60611 USA
[2] Inst BioMed Rsch & Innovat, Kobe, Hyogo, Japan
来源：
CIRCULATION | 2008年 / 118卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S536 / S537
页数：2
相关论文
共 50 条
  • [31] In vitro and preclinical activity of the novel AMD3100 CXCR4 antagonist in lymphoma models.
    Paul, S
    Mancuso, P
    Rabascio, C
    Gobbi, A
    Capillo, M
    Pruneri, G
    Martinelli, G
    Fricker, S
    Bridger, G
    Bertolini, F
    BLOOD, 2002, 100 (11) : 579A - 579A
  • [32] The chemokine receptor CXCR4 antagonist AMD3100 exerts deleterious effects in endotoxemia in vivo
    Seemann, S.
    Lupp, A.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2016, 389 (01) : S64 - S65
  • [33] The Effect of the CXCR4 Inhibitors, AMD3100 and AMD3465, in Multiple Myeloma Cell Homing and Its Interaction with the Bone Marrow Microenvironment.
    Runnels, Judith M.
    Azab, Abdel Kareem
    Pitsillides, Costas
    Farag, Jonathan
    Wu, Juwell
    Roccaro, Aldo N.
    Maiso, Patricia
    Lin, Charles P.
    Ghobrial, Irene M.
    BLOOD, 2009, 114 (22) : 725 - 725
  • [34] A pharmacokinetic/pharmacodynamic profile of the CXCR4 antagonist AMD3100 for the mobilization of hematopoietic progenitor cells.
    Lack, NA
    Dale, DC
    Calandra, G
    MacFarland, RT
    Badel, K
    Liles, WC
    BLOOD, 2003, 102 (11) : 115A - 115A
  • [35] Treatment with the CXCR4 Antagonist AMD3100 Enhances Antibody Mediated Killing in Disseminated Lymphoma Models
    Siders, William
    Hu, Yanping
    Gale, Matthew
    Jacques, Gary
    Fogle, Robert
    Shields, Jacqueline
    Garron, Carrie
    Kaplan, Johanne
    BLOOD, 2009, 114 (22) : 1064 - 1064
  • [36] THE EFFECT OF THE CXCR4 ANTAGONIST AMD3100 ON GLIOMA MIGRATION AND TUMOR INVASION IN THE GL261 MURINE MODEL
    Santovasi, Daniel
    Lukyanov, Eugene
    Esencay, Mine
    Zagzag, David
    Lim, Ilya G.
    Newcomb, Elizabeth W.
    NEURO-ONCOLOGY, 2009, 11 (05) : 639 - 639
  • [37] Cytotoxic drugs in combination with the CXCR4 antagonist AMD3100 as a potential treatment option for pediatric rhabdomyosarcoma
    Regenbogen, Stephan
    Stagno, Matias Julian
    Schleicher, Sabine
    Schilbach, Karin
    Boesmueller, Hans
    Fuchs, Joerg
    Schmid, Evi
    Seitz, Guido
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2020, 57 (01) : 289 - 300
  • [38] Increased sensitivity to bortezomib after mobilization of multiple myeloma cells with the CXCR4 antagonist AMD3100
    Wemeau, Mathieu
    Balkaran, Sandy
    Leleu, Xavier
    HEMATOLOGIE, 2009, 15 (03): : 194 - 196
  • [39] The CXCR4 Antagonist AMD3100 Has Dual Effects on Survival and Proliferation of Myeloma Cells In Vitro
    Kim, Ha-Yon
    Hwang, Ji-Young
    Kim, Seong-Woo
    Lee, Hyo-Jin
    Yun, Hwan-Jung
    Kim, Samyong
    Jo, Deog-Yeon
    CANCER RESEARCH AND TREATMENT, 2010, 42 (04): : 225 - 234
  • [40] Insights into the biology of mobilized cells through innovative treatment schedules of the CXCR4 antagonist AMD3100
    Bonig, Halvard
    Papayannopoulou, Thalia
    BLOOD, 2007, 110 (11) : 661A - 661A
12345